📊 BRNS Key Takeaways
Is Barinthus Biotherapeutics plc. (BRNS) a Good Investment?
Barinthus is a pre-revenue biopharmaceutical company in clinical development with no product sales, generating -$66.4M net losses and -$48.0M operating cash burn. Despite adequate cash reserves of $70.5M providing 12-14 months of runway at current burn rates, the company faces existential risk with zero revenue generation, deeply negative profitability metrics (ROE -89.5%, ROA -67.7%), and no demonstrated path to commercialization or profitability.
Barinthus Biotherapeutics shows the typical profile of a pre-revenue biotech with no current commercial traction, large operating losses, and deeply negative returns on equity and assets. Its balance sheet is a meaningful offset, with substantial cash, strong liquidity, and no long-term debt, but the current fundamentals depend heavily on continued cash funding rather than internally generated business performance. Until revenue generation or a clear improvement in cash burn emerges, the fundamental profile remains weak.
Why Buy Barinthus Biotherapeutics plc. Stock? BRNS Key Strengths
- Strong liquidity position with $70.5M cash and 7.77x current ratio
- No long-term debt providing financial flexibility
- Adequate working capital to fund near-term operations
- Strong liquidity with $70.46M in cash and current ratio of 7.77x
- Debt-free balance sheet reduces financial distress risk
- Equity base remains positive at $74.21M, providing some balance sheet cushion
BRNS Stock Risks: Barinthus Biotherapeutics plc. Investment Risks
- Zero revenue with -100% YoY decline indicates failed commercialization or clinical programs
- Severe cash burn of -$48.0M annually will exhaust reserves within 12-14 months without capital raise
- No product portfolio generating revenue; entirely dependent on clinical trial success with high failure risk
- Negative ROE (-89.5%) and ROA (-67.7%) indicate value destruction and poor asset utilization
- No insider buying activity suggests limited management confidence in company direction
- Zero revenue and no gross profit indicate no current operating business scalability
- Large annual net loss of $66.43M and negative free cash flow of $48.02M imply continued capital consumption
- Negative ROE and ROA show weak capital efficiency and poor underlying profitability
Key Metrics to Watch
- Cash balance and runway - critical indicator of survival timeline
- Clinical trial progression and regulatory milestones for pipeline candidates
- Operating cash flow trend and achievement of clinical endpoints
- Potential capital raises or financing events to extend runway
- Revenue generation from any approved or commercialized products
- Quarterly cash burn relative to cash balance
- Any sustained revenue generation from partnerships, licensing, or commercialization
Barinthus Biotherapeutics plc. (BRNS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.77x current ratio provides a solid financial cushion.
BRNS Profit Margin, ROE & Profitability Analysis
BRNS vs Healthcare Sector: How Barinthus Biotherapeutics plc. Compares
How Barinthus Biotherapeutics plc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Barinthus Biotherapeutics plc. Stock Overvalued? BRNS Valuation Analysis 2026
Based on fundamental analysis, Barinthus Biotherapeutics plc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Barinthus Biotherapeutics plc. Balance Sheet: BRNS Debt, Cash & Liquidity
BRNS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Barinthus Biotherapeutics plc.'s revenue has grown significantly by 210% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.55 indicates the company is currently unprofitable.
BRNS Revenue Growth, EPS Growth & YoY Performance
BRNS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$8.1M | $-0.21 |
| Q3 2024 | N/A | -$8.1M | $-0.21 |
| Q2 2024 | N/A | -$16.9M | $-0.43 |
| Q1 2024 | N/A | -$15.5M | $-0.40 |
| Q3 2023 | $802.0K | $8.2M | $0.22 |
| Q2 2023 | $334.0K | $15.7M | $0.41 |
| Q1 2023 | $468.0K | $2.6M | $0.07 |
| Q3 2022 | $19.0K | -$4.6M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Barinthus Biotherapeutics plc. Dividends, Buybacks & Capital Allocation
BRNS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Barinthus Biotherapeutics plc. (CIK: 0001828185)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BRNS
What is the AI rating for BRNS?
Barinthus Biotherapeutics plc. (BRNS) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BRNS's key strengths?
Claude: Strong liquidity position with $70.5M cash and 7.77x current ratio. No long-term debt providing financial flexibility. ChatGPT: Strong liquidity with $70.46M in cash and current ratio of 7.77x. Debt-free balance sheet reduces financial distress risk.
What are the risks of investing in BRNS?
Claude: Zero revenue with -100% YoY decline indicates failed commercialization or clinical programs. Severe cash burn of -$48.0M annually will exhaust reserves within 12-14 months without capital raise. ChatGPT: Zero revenue and no gross profit indicate no current operating business scalability. Large annual net loss of $66.43M and negative free cash flow of $48.02M imply continued capital consumption.
What is BRNS's revenue and growth?
Barinthus Biotherapeutics plc. reported revenue of $0.0.
Does BRNS pay dividends?
Barinthus Biotherapeutics plc. does not currently pay dividends.
Where can I find BRNS SEC filings?
Official SEC filings for Barinthus Biotherapeutics plc. (CIK: 0001828185) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BRNS's EPS?
Barinthus Biotherapeutics plc. has a diluted EPS of $-1.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BRNS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Barinthus Biotherapeutics plc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BRNS stock overvalued or undervalued?
Valuation metrics for BRNS: ROE of -89.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BRNS stock in 2026?
Our dual AI analysis gives Barinthus Biotherapeutics plc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BRNS's free cash flow?
Barinthus Biotherapeutics plc.'s operating cash flow is $-48.0M, with capital expenditures of $37.0K.
How does BRNS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -89.5% (avg: 15%), current ratio 7.77 (avg: 2).